Discussing the problem of venetoclax resistance: time of occurrence, clinical manifestations and response strategies

Venetoclax, an innovative drug targeting the BCL-2 (BCL-2) protein, has been It has demonstrated significant efficacy in the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). However, with the deepening of clinical application, some patients have developed resistance to venetoclax, which undoubtedly brings new challenges to treatment. This article will discuss in detail the occurrence time, clinical manifestations and response strategies of venetoclax resistance, with a view to providing a reference for doctors and patients.

1. Time of occurrence of venetoclax resistance

The resistance time to venetoclax varies among individual patients and is difficult to generalize. Generally speaking, resistance may develop within months to years after treatment is initiated. In the early stages of treatment, venetoclax can often effectively inhibit the growth of tumor cells. However, as treatment continues, some tumor cells may gradually adapt to the inhibitory effect of the drug, leading to the emergence of drug resistance.

Resistance mechanisms are complex and diverse and may involve multiple factors such as gene mutations, activation of alternative survival signals, and changes in the tumor microenvironment. Tumor cells change the expression or function of BCL-2 through gene mutations, reducing the efficacy of venetoclax; at the same time, they can also activate other survival signaling pathways and reduce their dependence on BCL-2, thus evading the effects of venetoclax. In addition, changes in the tumor microenvironment, such as changes in the extracellular matrix and infiltration of immune cells, may also affect the efficacy of drugs.

2. Clinical manifestations of venetoclax resistance

Patients may develop a series of signs of disease progression after developing resistance to venetoclax. These signs mainly include abnormalities in hematological indicators, such as decreases in white blood cell, hemoglobin, and platelet counts; at the same time, patients may experience increased fatigue, bleeding tendencies, and increased risk of infection. In addition, imaging studies such as CT or MRI may show an increase in tumor burden, further confirming disease progression.

3. Strategies to deal with venetoclax resistance

Faced with the phenomenon of venetoclax resistance, doctors usually adopt a series of strategies to deal with it. First, doctors will conduct a comprehensive assessment of the patient's condition, including genetic testing and molecular analysis, to determine the mechanism of resistance. These tests help doctors develop more personalized treatment plans.

Once resistance is confirmed, doctors may consider changing medications. Depending on the patient's specific situation, doctors may choose other targeted drugs, chemotherapy drugs or immunotherapy drugs as alternatives. For example, in CLL patients, when BCL-2 is mutated, other targeted drugs such as ibrutinib (Ibrutinib) may be used to replace venetoclax.

In addition to changing medications, combination therapy is also an effective strategy. By combining drugs with different mechanisms, drug resistance can be overcome and efficacy enhanced. For example, combining venetoclax with other drugs such as azacitidine or decitabine may result in better treatment effects.

In some cases, doctors may consider maintenance treatment. That is, after the development of drug resistance, continue to use venetoclax, but reduce the dose to reduce side effects, and closely observe the patient's response to treatment. This strategy helps prolong patient survival and improve quality of life.

As scientific research continues to advance, new treatment options are emerging, providing new hope for drug-resistant patients. New drugs and treatment strategies targeting drug resistance mechanisms are being continuously developed, and these new treatments are expected to bring better therapeutic effects to drug-resistant patients. In addition, clinical trials are also an important option, through which patients can gain access to new drugs and contribute to medical research.

In summary, the phenomenon of venetoclax resistance is an important challenge in clinical practice. The time when drug resistance occurs varies between individuals, so patients need to pay close attention to changes in their condition and maintain close communication with their doctors. Once drug resistance is discovered, patients should seek medical treatment promptly, conduct a comprehensive assessment, and develop reasonable response strategies. Through personalized treatment plans and continuously updated treatment options, many drug-resistant patients still have the opportunity to obtain effective treatment and improve their quality of life and survival.